Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial-Reference-Cited by-同舟云学术

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial

Published:2021-12 Issue: Volume:111 Page:106736
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Luger Selina M.^ORCID,Wang Victoria X.,Rowe Jacob M.,Litzow Mark R.,Paietta Elisabeth,Ketterling Rhett P.,Lazarus Hillard,Rybka Witold B.,Craig Michael D.,Karp Judith,Cooper Brenda W.,Makary Adel Z.,Kaminer Lynne S.,Appelbaum Frederick R.,Larson Richard A.,Tallman Martin S.

Funder

National Institutes of Health

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference27 articles.

1. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia;Raponi;BMC Cancer,2004

2. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial;Karp;Blood,2001

3. A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia;Kirschbaum;Leukemia,2011

4. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia;Harousseau;Blood,2007

5. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia;Lancet;Blood,2007

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML;Cell Reports Medicine;2023-11

2. Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE);Cancers;2023-04-24

3. Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax inFLT3-andKIT-Mutant AML;2022-12-03